| heart failure | versus placebo or no treatment No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| VHeFT III, 1997 | felodipine vs placebo | | | all-cause death 1.08 [0.67; 1.73] | | Kassis, 1987 | felodipine vs placebo | | | | | Littler, 1995 | Felodipine vs placebo | | | all-cause death 1.35 [0.23; 7.95] | | felodipine vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| VHeFT III, 1997 | felodipine 5mg twice daily (n=224) vs. placebo (n=226) | male patient over 18 years with heart failure | Double blind Parallel groups Sample size: 224/226 Primary endpoint: exercise tolerance FU duration: mean 18mo (range 3-39 mo) | | Kassis, 1987 | felodipine 10 mg twice daily (n=18) vs. placebo (n=18) | patients on conventional therapy for severe CHF | Double blind Cross over Sample size: 18/18 Primary endpoint: haemodynamic FU duration: 3 weeks | | Littler, 1995 | felodipine extended release 2.5-10mg twice daily (in addition to existing background medication) for 12 weeks (n=132) vs. placebo (n=119) | patients with NYHA class II-III stable congestive heart failure despite treatment with ACE inhibitors, diuretic and digoxin or any combinaison of these drugs | Double blind Parallel groups Sample size: 132/119 Primary endpoint: exercise tolerance FU duration: 3 months | | Kassis, 1990 | felopidine 10 mg BID (n=10) vs. placebo (n=10) | severe congestive heart failure (NYHA class III) | Double blind Parallel groups Sample size: 10/10 Primary endpoint: haemodynamic FU duration: 6 months |
|
| heart failure | versus angiotensin-converting enzyme inhibitors No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| felodipine vs enalapril | | | | | felodipine vs enalapril | | | |
| Trial | Treatments | Patients | Method |
|---|
| Dunselman, 1990 | felodipine 10 mg b.i.d. (n=9) vs. enalapril 10 mg b.i.d. (n=11) | patients with congestive heart failure due to ischaemic heart disease and NYHA class III | Double blind Sample size: 9/11 Primary endpoint: cardiopulmonary exercise tests FU duration: 4 months | | De Vries, 1995 | felodipine 2.5mg twice daily (n=22) vs. enalapril 2.5mg twice daily (n=24) | patients NYHA class II-III with left ventricular ejection fraction <0.4, symptoms of CHD despite therapy with diuretics and digoxin | Double blind Parallel groups Sample size: 22/24 Primary endpoint: cardiopulmonary exercise tests FU duration: 4 months |
|
